Roche strikes obesity drug licensing deal worth up to $1.16 bln with Chinese Rona Therapeutics
Roche strikes obesity drug licensing deal worth up to $1.16 bln with Chinese Rona Therapeutics Reuters
Covered in this story
Call it yourself
No calls on $ROG.SW yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Roche Holding →Summary aggregated from Reuters's public RSS feed. The full reporting belongs to Reuters — please read it on their site.